Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway

Background: Nonalcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver diseases worldwide. At present, there are no effective pharmacological therapies for NAFLD except lifestyle intervention-mediated weight loss. Atractylenolide III (ATL III), the major bioactive component...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qian, Tan, Jia-Xin, He, Yong, Bai, Fang, Li, Shi-Wei, Hou, Yi-Wen, Ji, Long-Shan, Gao, Ya-Ting, Zhang, Xin, Zhou, Zhen-Hua, Yu, Zhuo, Fang, Miao, Gao, Yue-Qiu, Li, Man
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898375/
https://www.ncbi.nlm.nih.gov/pubmed/35280674
http://dx.doi.org/10.7150/ijbs.68873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898375/
https://www.ncbi.nlm.nih.gov/pubmed/35280674
http://dx.doi.org/10.7150/ijbs.68873

Ejemplares similares